Overview

* Abbott Q3 sales rose 6.9% to $11.4 billion, organic growth at 5.5%, excluding COVID-19 testing sales

* Adjusted EPS for Q3 was $1.30, in-line with analyst expectations

* Abbott reaffirms full-year 2025 guidance for organic sales growth and adjusted EPS

Outlook

* Abbott reaffirms full-year 2025 organic sales growth guidance of 7.5% to 8.0%

* Abbott narrows full-year 2025 adjusted EPS guidance to $5.12-$5.18

Result Drivers

* MEDICAL DEVICES GROWTH - Strong sales growth in Medical Devices driven by Diabetes Care and Electrophysiology

* DIAGNOSTICS DECLINE - Diagnostics sales declined due to reduced COVID-19 testing demand

* REGULATORY APPROVALS - New approvals in Japan and Europe for TriClip and Navitor contributed to performance

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Met $1.30 $1.30

Adjusted (23

EPS Analysts

)

Q3 EPS $0.94

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Abbott Laboratories ( ABT ) is $143.56, about 7.2% above its October 14 closing price of $133.27

* The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)